CORNEA EWAP JUNE 2022 23 viability of afferent trigeminal stimulation for varenicline. Dr. Sheppard called the results from the Phase 3 clinical trial exciting, noting that it produced excellent sign and symptom improvements and is thought to produce a classic physiologic tripartite tear film. Dr. -heppard also said a significant subset of patients who don’t like drops or who have issues with drop delivery, tremors, arthritis, poor depth perception, those who are already on other drops, or who don’t want to use drops for aesthetic purposes will accept intranasal delivery. He said patients are familiar with nasal sprays, such as those for allergies, which may increase acceptance as well. Dr. Sheppard described TYRVAYA as not only a novel pathway but a novel delivery system. “It’s dually innovative in this regard,” he said. EWAP Editors’ note: Dr. de Luise is Assistant Clinical Professor of Ophthalmology, Yale University School of Medicine, New Haven, Connecticut, and declared no releÛant finanVial interests° r° Galor is Assistant Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida. Dr. Sheppard is President, Virginia Eye Consultants, Norfolk, Virginia. Drs. Galor and Sheppard declared interests with Oyster Point Pharma. Adv 1/2 V Feather Safety
RkJQdWJsaXNoZXIy Njk2NTg0